Show simple item record

dc.contributor.authorSpain, L
dc.contributor.authorSchmid, T
dc.contributor.authorGore, M
dc.contributor.authorLarkin, J
dc.date.accessioned2017-04-10T16:17:05Z
dc.date.issued2017-04-01
dc.identifier.citationEuropean journal of cancer (Oxford, England : 1990), 2017, 75 pp. 243 - 244
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/575
dc.identifier.eissn1879-0852
dc.identifier.doi10.1016/j.ejca.2016.12.040
dc.formatPrint-Electronic
dc.format.extent243 - 244
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectMelanoma
dc.subjectAntibodies, Monoclonal
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectIpilimumab
dc.subjectNivolumab
dc.titleEfficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features.
dc.typeJournal Article
dcterms.dateAccepted2016-12-06
rioxxterms.versionofrecord10.1016/j.ejca.2016.12.040
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of cancer (Oxford, England : 1990)
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume75
pubs.embargo.terms12 months
icr.researchteamMelanoma and Kidney Cancer
dc.contributor.icrauthorSpain, Lavinia


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record